Vivani Medical

Vivani Medical

Vivani Medical was formed in 2018 when Adam Mendelsohn — a biomedical engineer by training — acquired and rebranded a dormant public listing, structuring the entity as a dual-purpose platform: an implantable drug-device company in development, and a listed vehicle with the capacity to hold a portfolio of minority investments. Mendelsohn's prior venture, Nano Precision Medical, was folded into the new entity, forming the technological core around a patented subdermal implant designed for ultra-long-duration drug delivery. The firm's investment strategy blurs the categories of operating company and family office. Its central asset is the NanoPortal implant, which targets chronic disease management — particularly Type 2 diabetes and obesity — by releasing a GLP-1 receptor agonist over six months from a single matchstick-sized titanium device. Deployment numbers are not public. Asset-mix characteristics are concentrated: one in-development biotech platform with regulatory risk, one listed shell with nominal public float, and a small number of undisclosed minority stakes held through the publicly traded parent, Vivani Medical, Inc. (NASDAQ: VANI). The geographic footprint is Northern California. Team size is undisclosed. Mendelsohn retains tight operational control, serving simultaneously as CEO and board member, while the public-company structure forces a degree of governance formality — independent directors, SEC filings — that single-family offices typically avoid. Vivani does not maintain disclosed philanthropic structures or parallel vehicles. In August 2024, the company completed a reverse stock split to maintain NASDAQ listing compliance, a maneuver that highlighted the tension between its operating-company needs and its public-market shell architecture. Vivani's defining shape is its hybrid structure: a public company that operates like a private family office with one big illiquid biotech bet and no obligation to report quarterly strategy shifts to external limited partners. The NASDAQ listing, combined with Mendelsohn's undisclosed ownership stake, gives the entity a permanent-capital quality that private family offices often seek through trust structures — at the cost of market-priced equity volatility.